Literature DB >> 21789693

[The presymptomatic stage of neurodegenerative disorders].

C Klein1, J Hagenah, B Landwehrmeyer, T Münte, T Klockgether.   

Abstract

Neurodegenerative disorders, such as Huntington's disease, spinocerebellar ataxias, Parkinson's disease or Alzheimer's disease, manifest in adult age with insidiously developing, slowly progressing symptoms. At this stage, most patients consult a doctor, and a definite diagnosis can be made. It is, however, well established that the manifest disease is preceded by a presymptomatic disease stage that may last for years. A striking example is Parkinson's disease, in which more than half of the dopaminergic neurons of the substantia nigra are lost before motor symptoms appear. Studies of the presymptomatic stage of neurodegenerative disorders are pivotal for an advanced understanding of these disorders and the development of preventive strategies aimed at postponing the clinical onset of these disorders. It is therefore important to identify the earliest and most sensitive clinical signs and biological markers that herald the onset of the illness. Furthermore, studies of presymptomatic disease stages are important because they may help to unravel compensatory mechanisms responsible for apparently normal brain function despite ongoing neurodegeneration.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21789693     DOI: 10.1007/s00115-011-3258-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  31 in total

Review 1.  Neuropathology of Alzheimer's disease: what is new since A. Alzheimer?

Authors:  E Braak; K Griffing; K Arai; J Bohl; H Bratzke; H Braak
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1999       Impact factor: 5.270

2.  The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.

Authors:  H Jacobi; P Bauer; P Giunti; R Labrum; M G Sweeney; P Charles; A Dürr; C Marelli; C Globas; C Linnemann; L Schöls; M Rakowicz; R Rola; E Zdzienicka; T Schmitz-Hübsch; R Fancellu; C Mariotti; C Tomasello; L Baliko; B Melegh; A Filla; C Rinaldi; B P van de Warrenburg; C C P Verstappen; S Szymanski; J Berciano; J Infante; D Timmann; S Boesch; S Hering; C Depondt; M Pandolfo; J-S Kang; S Ratzka; J Schulz; S Tezenas du Montcel; T Klockgether
Journal:  Neurology       Date:  2011-08-10       Impact factor: 9.910

3.  Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan.

Authors:  P N Wang; J F Lirng; K N Lin; F C Chang; H C Liu
Journal:  Neurobiol Aging       Date:  2006-12       Impact factor: 4.673

4.  An item response analysis of the motor and behavioral subscales of the unified Huntington's disease rating scale in huntington disease gene expansion carriers.

Authors:  Anthony L Vaccarino; Karen Anderson; Beth Borowsky; Kevin Duff; Joseph Giuliano; Mark Guttman; Aileen K Ho; Michael Orth; Jane S Paulsen; Terrence Sills; Daniel P van Kammen; Kenneth R Evans
Journal:  Mov Disord       Date:  2011-03-02       Impact factor: 10.338

5.  Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis.

Authors:  Sarah J Tabrizi; Rachael I Scahill; Alexandra Durr; Raymund Ac Roos; Blair R Leavitt; Rebecca Jones; G Bernhard Landwehrmeyer; Nick C Fox; Hans Johnson; Stephen L Hicks; Christopher Kennard; David Craufurd; Chris Frost; Douglas R Langbehn; Ralf Reilmann; Julie C Stout
Journal:  Lancet Neurol       Date:  2010-12-02       Impact factor: 44.182

Review 6.  [Imaging of genetic aspects of Parkinson's disease].

Authors:  N Brüggemann; J Vegt; C Klein; H R Siebner
Journal:  Nervenarzt       Date:  2010-10       Impact factor: 1.214

7.  Evidence for specific phases in the development of human neuromelanin.

Authors:  G M Halliday; H Fedorow; C H Rickert; M Gerlach; P Riederer; K L Double
Journal:  J Neural Transm (Vienna)       Date:  2006-04-11       Impact factor: 3.575

8.  Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit.

Authors:  C Eggers; A Schmidt; J Hagenah; N Brüggemann; J C Klein; V Tadic; L Kertelge; M Kasten; F Binkofski; H Siebner; B Neumaier; G R Fink; R Hilker; C Klein
Journal:  Neurology       Date:  2010-06-01       Impact factor: 9.910

9.  Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls.

Authors:  Jason P Lerch; Jens Pruessner; Alex P Zijdenbos; D Louis Collins; Stefan J Teipel; Harald Hampel; Alan C Evans
Journal:  Neurobiol Aging       Date:  2006-11-13       Impact factor: 4.673

10.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

View more
  7 in total

Review 1.  Early diagnosis and therapy of Parkinson's disease: can disease progression be curbed?

Authors:  Sagar Kansara; Akash Trivedi; Sheng Chen; Joseph Jankovic; Weidong Le
Journal:  J Neural Transm (Vienna)       Date:  2012-06-26       Impact factor: 3.575

Review 2.  Diagnosis and treatment of chorea syndromes.

Authors:  Andreas Hermann; Ruth H Walker
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

3.  Unaffected first-degree relatives of essential tremor cases have more imbalance than age-matched control subjects.

Authors:  Elan D Louis; James H Meyers; Ashley D Cristal; Ruby Hickman; Pam Factor-Litvak
Journal:  Parkinsonism Relat Disord       Date:  2018-03-13       Impact factor: 4.891

4.  [Neurocognitive disorders in DSM-5: pervasive changes in the diagnostics of dementia].

Authors:  W Maier; U B Barnikol
Journal:  Nervenarzt       Date:  2014-05       Impact factor: 1.214

5.  [Advances in the diagnostics of Alzheimer's disease].

Authors:  U Fiedler; J Wiltfang; N Peters; J Benninghoff
Journal:  Nervenarzt       Date:  2012-05       Impact factor: 1.214

6.  In vivo characterization of white matter pathology in premanifest huntington's disease.

Authors:  Jiaying Zhang; Sarah Gregory; Rachael I Scahill; Alexandra Durr; David L Thomas; Stéphane Lehericy; Geraint Rees; Sarah J Tabrizi; Hui Zhang
Journal:  Ann Neurol       Date:  2018-09-15       Impact factor: 10.422

Review 7.  Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer's disease.

Authors:  Diane Bairamian; Sha Sha; Cynthia A Lemere; Slavica Krantic; Nathalie Rolhion; Harry Sokol; Guillaume Dorothée
Journal:  Mol Neurodegener       Date:  2022-03-05       Impact factor: 14.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.